• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

After forcing workers back to the office, Goldman Sachs and JPMorgan Chase are now letting their staff work remotely—but only for the World Cup

2

The Pentagon said Iran War costs $29 billion, but the real cost is closer to $200 billion—and counting

3

Amazon's record Prime Day masks a darker truth: Americans are spending more and getting less

1

After forcing workers back to the office, Goldman Sachs and JPMorgan Chase are now letting their staff work remotely—but only for the World Cup

2

The Pentagon said Iran War costs $29 billion, but the real cost is closer to $200 billion—and counting

3

Amazon's record Prime Day masks a darker truth: Americans are spending more and getting less
Health

Germany’s new health minister delivers a bombshell: The country doesn’t have enough COVID-19 vaccines

Christiaan Hetzner
By
Christiaan Hetzner
Christiaan Hetzner
Senior Reporter
Down Arrow Button Icon
Christiaan Hetzner
By
Christiaan Hetzner
Christiaan Hetzner
Senior Reporter
Down Arrow Button Icon
December 15, 2021, 7:54 AM ET
Add Fortune on Google for similar content.

Germany is running out of COVID-19 vaccines—even before Omicron can begin to wreak havoc. 

Angela Merkel’s successor, Olaf Scholz, reaffirmed on Wednesday his goal as the new chancellor of administering 30 million jabs—whether as first, second, or booster doses—by the end of this year. Yet the push to defeat Delta could leave the country out of stock just as the new, highly contagious Omicron strain threatens to spread like wildfire.

After assuming responsibility last week for the country’s effort to defeat the virus, Federal Health Minister Karl Lauterbach took inventory of Germany’s supply, only to discover it faces a shortage for the first quarter of 2022.

“It’s true that we have too few doses,” he told German public broadcaster ARD on Tuesday evening. “That surprised many of us following the audit, myself included.”

Perhaps the most controversial figure in the new cabinet because of his reputation as a loose cannon, Lauterbach said he was exploring all legal options at his disposal to acquire more doses within the limits of coordinated EU-wide vaccine procurement policies.

EU summit

On Thursday, leaders from the 27 EU member states are expected to debate the COVID situation and the threat presented by Omicron at a regular summit meeting of the European Council in Brussels.

“We will also address global cooperation, including how we can step up our efforts and remove bottlenecks in the sharing and administration of vaccines,” EU Council President Charles Michel wrote on Tuesday in his invitation letter to the heads of government.

Lauterbach’s discovery of Germany’s shortage is not the first warning sign related to Germany’s supply, however. His predecessor Jens Spahn came under heavy fire after he said last month the government would begin rationing supply of the domestically popular BioNTech vaccine Comirnaty, developed in Germany and licensed for sale in most of the world by partner Pfizer. 

Instead, more people would have to accept Spikevax from U.S.-based Moderna, according to the former health minister. Not only was Spahn criticized for seeming to discourage Germans from being inoculated, it emerged that supplies of the U.S. alternative mRNA vaccine were nearing their expiration date and would have to be otherwise destroyed.

Radical measures

On Wednesday, Chancellor Scholz tried to strike a confident note, telling Germany’s lower house of parliament his year-end goal remained within reach, with 19 million doses, or nearly two-thirds, already administered to date. 

“The federal government will not rest for a single solitary moment; rather we will continue to pull every possible lever at our disposal until each of us has fully returned to our previous lives and we have regained all our freedoms,” he said during his government’s first policy address to the Bundestag.

In the coming weeks, the lower house is expected to hold an open vote over a vaccine mandate that could go into effect as early as February.

The impending first-quarter 2022 shortage ironically comes only weeks after reports emerged in the summer that the country, among the least vaccinated in Western Europe, had ordered too many doses. At the time, few people expected the fourth wave to be Germany’s worst, and Omicron had not yet been discovered.

The surplus doses were meant to be donated to international body COVAX for distribution to developing countries, but that had been hampered by contractual obligations. Manufacturers like BioNTech must give final approval, a measure introduced to minimize their liability. 

The waning supplies now threaten to derail Germany’s COVID efforts, however, since boosters are expected to be a key tool in defusing the Delta surge before Omicron can potentially overwhelm health authorities. 

In the U.K., new estimates suggest the country should surpass South Africa as the epicenter of the highly contagious Omicron variant, if indeed it has not already.

When asked whether more restrictions could be imposed in the coming days, Lauterbach reaffirmed his pledge that the ministry under his leadership would rely more heavily on scientific advice when formulating policy.

“If the expert opinion should be a recommendation to implement radical measures,” he told ARD, “then we would certainly consider that.”

Never miss a story: Follow your favorite topics and authors to get a personalized email with the journalism that matters most to you.

About the Author
Christiaan Hetzner
By Christiaan HetznerSenior Reporter
Instagram iconLinkedIn iconTwitter icon

Christiaan Hetzner is a former writer for Fortune, where he covered Europe’s changing business landscape.

See full bioRight Arrow Button Icon
Add Fortune on Google for similar content.

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

Helix Plus Lead
Healthmattresses
The Best Early 4th of July Mattress Sales of 2026: Saatva, Helix, and More
By Christina SnyderJune 24, 2026
3 hours ago
mg
CommentaryHealth
The ‘tech neck’ time bomb: why 43 million young Americans could cripple U.S. health care within a generation
By Michael GerlingJune 24, 2026
10 hours ago
UPS workers process boxes in a sorting facility.
North AmericaUPS
UPS is shelling out nearly $50 million on temperature-controlled facilities to meet the booming demand for GLP-1 deliveries
By Sasha RogelbergJune 23, 2026
1 day ago
dr
HealthCancer
The U.S. cut cancer deaths by 34% since 1991—but not in 458 rural counties
By Arthur Cosby and The ConversationJune 23, 2026
1 day ago
Woman hides from the sun in front of Big Ben in London
EconomyEurope
‘London isn’t just calling—it’s cooking.’ Europe’s largest economies face over $600 billion in heat-driven losses by 2030
By Tristan BoveJune 23, 2026
1 day ago
Doctor giving patient injection in volunteer clinic
HealthHealth
For the first time ever, no young women in England died of cervical cancer. In the U.S., RFK Jr.’s vaccine skepticism stalls HPV progress
By Catherina GioinoJune 23, 2026
1 day ago

Most Popular

After forcing workers back to the office, Goldman Sachs and JPMorgan Chase are now letting their staff work remotely—but only for the World Cup
Success
After forcing workers back to the office, Goldman Sachs and JPMorgan Chase are now letting their staff work remotely—but only for the World Cup
By Orianna Rosa RoyleJune 23, 2026
1 day ago
The Pentagon said Iran War costs $29 billion, but the real cost is closer to $200 billion—and counting
Economy
The Pentagon said Iran War costs $29 billion, but the real cost is closer to $200 billion—and counting
By Jacqueline MunisJune 24, 2026
15 hours ago
Amazon's record Prime Day masks a darker truth: Americans are spending more and getting less
Retail
Amazon's record Prime Day masks a darker truth: Americans are spending more and getting less
By Nick LichtenbergJune 24, 2026
7 hours ago
Ray Dalio just finished a 10-day trip to China. He says global leaders know America 'doesn’t have what it takes to fight to maintain its empire'
Asia
Ray Dalio just finished a 10-day trip to China. He says global leaders know America 'doesn’t have what it takes to fight to maintain its empire'
By Nick LichtenbergJune 24, 2026
8 hours ago
Current price of oil as of June 23, 2026
Personal Finance
Current price of oil as of June 23, 2026
By Joseph HostetlerJune 23, 2026
1 day ago
Current price of gold as of June 23, 2026
Personal Finance
Current price of gold as of June 23, 2026
By Danny BakstJune 23, 2026
1 day ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.